Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03448042 · ClinicalTrials.gov registry record · Phase 1

A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

A Phase 1 study of Solid Tumors, sponsored by Genentech.

Active
Registry status
Phase 1
Development phase
123
Enrollment target
20
Study locations

NCT03448042 is a Phase 1 study of Solid Tumors that is active but no longer recruiting, run by Genentech. The registered enrollment target is 123 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03448042, a Phase 1 study of Solid Tumors, is active but no longer recruiting, sponsored by Genentech.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
123 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate the safety, tolerability, and pharmacokinetics of Runimotamab administered intravenously as a single agent and in combination with Trastuzumab in participants with locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-expressing cancers.

Conditions Studied

Solid Tumors

Interventions

  • DRUG Trastuzumab
  • DRUG Tocilizumab
  • DRUG Runimotamab

Study Locations (20)

Other

  • Grand Hopital de Charleroi asbl - Charleroi
  • Rigshospitalet-Blegdamsvej 9 - Copenhagen
  • Institut Claudius Regaud - Toulouse
  • National Cancer Center East - Chiba
  • Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis - Amsterdam
  • National Cancer Centre - Singapore
  • Asan Medical Center - Seoul
  • Seoul National University Hospital - Seoul

Connecticut

  • Yale University - New Haven

Michigan

  • Washington University - Saint Louis

New York

  • Memorial Sloan Kettering Cancer Center - New York

Tennessee

  • SCRI Oncology Partners - Nashville

Texas

  • MD Anderson Cancer Center - Houston

Victoria

  • Peter MacCallum Cancer Centre - Melbourne

Ontario

  • Princess Margaret Hospital - Toronto

Trial Details

FieldValue
Enrollment Target 123 participants
Start Date 2018-06-06
Est. Completion 2026-11-30
Phase Phase 1

Sponsor

Genentech

332 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03448042

The ClinicalTrials.gov registry entry for NCT03448042 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (57% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which Trastuzumab is the first listed.

NCT03448042 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Connecticut, Michigan.

Frequently Asked Questions

What is clinical trial NCT03448042 about?

NCT03448042 is a clinical study titled "A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers". This study will evaluate the safety, tolerability, and pharmacokinetics of Runimotamab administered intravenously as a single agent and in combination with Trastuzumab in participants with locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-expressing cancers.

What is the current status of trial NCT03448042?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 123 participants. The study started on 2018-06-06. Estimated completion is 2026-11-30.

What conditions does trial NCT03448042 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT03448042?

The interventions under investigation include: Trastuzumab (DRUG), Tocilizumab (DRUG), Runimotamab (DRUG).

Who is sponsoring clinical trial NCT03448042?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03448042 being conducted?

This trial has 20 study locations across Connecticut, Michigan, New York, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumors

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.